v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:      
Net loss $ (12,564) $ (7,472) $ (5,883)
Adjustments to the profit or loss items:      
Depreciation and amortization 234 482 538
Impairment of an intangible asset 115 1,344 1,042
Cost of share-based payment 867 569 196
Impairment of loan (see note 8c) 5,973
Subsidiaries’ cost of share-based payment (see note 25) 321
Finance income, net (1,998) (897) (2,205)
Equity losses 500 429 210
Deemed stock exchange listing expense 1,410
Gain on sale of an associate accounted for under the equity method (2,231)
Losses from remeasurement of investment in financial assets 1,791 305 1,048
Total adjustments to the profit or loss 6,982 2,232 829
Working capital adjustments:      
Decrease in trade receivables 12 55
Decrease (increase) in other accounts receivable 790 (535) (409)
Decrease (increase) in inventory 38 629 (74)
Increase (decrease) in trade payables (164) 25 (397)
Increase (decrease) in other payables 55 20 (8)
Increase (decrease) in related parties 726 (15)
Working capital 1,445 136 (833)
Net cash used in operating activities (4,137) (5,104) (5,887)
Cash flows from investing activities:      
Withdrawal of (investment in) restricted bank deposits 45 (5)
Withdrawal of (investment in) short-term bank deposits 3,000 (3,000)
Sale of property and equipment 8
Investment in an associate accounted for under the equity method (100) (600) (400)
Loan to related parties (2,000) (4,078)
Investments in financial assets (689)
Proceeds from sale of an affiliate accounted for under the equity method (see note 7) 700
Net cash used in investing activities (1,400) (1,625) (4,094)
Cash flows from financing activities:      
Proceeds from issuance of share capital (net of issuance expenses) 2,262 6,255 5,552
Proceeds from exercise of warrants 1,121
Sale of non-controlling interest in a subsidiary 2,985
Repayment of loans 192
Receipt of loans 356
Proceeds from deemed issuance of shares by a subsidiary (see (b) below) 710
Proceeds from issuance of convertible debentures (see note 18i) 3,990
Interest paid on lease liability (5) (8) (7)
Repayment of lease liability (38) (54) (47)
Net cash provided by financing activities 8,588 6,193 8,483
Increase (decrease) in cash 3,051 (536) (1,498)
Cash at the beginning of the period 1,540 2,076 3,574
Cash at the end of the period 4,591 1,540 2,076
(a) Significant non-cash financing and investing activities:      
Right-of-use asset recognized with corresponding lease liability 75 102
Investment in financial asset 288
Exchange of MitoCareX shares with Nexentis Inc. shares (see Note 7) 2,027
Conversion of convertible debentures $ 2,212